Related references
Note: Only part of the references are listed.Acquired qnrVC1 and bla NDM-1 resistance markers in an international high-risk Pseudomonas aeruginosa ST773 clone
Bela Kocsis et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2019)
Carbapenem inactivation: a very affordable and highly specific method for phenotypic detection of carbapenemase-producing Pseudomonas aeruginosa isolates compared with other methods
Mohammad Taghi Akhi et al.
JOURNAL OF CHEMOTHERAPY (2017)
Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods
Frieder Schaumburg et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria
Mark D. Gonzalez et al.
ANNALS OF LABORATORY MEDICINE (2017)
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates
Romney M. Humphries et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain
Ester del Barrio-Tofino et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds
Mordechai Grupper et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa
Pablo A. Fraile-Ribot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Comparison of Verona Integron-Borne Metallo-β-Lactamase (VIM) Variants Reveals Differences in Stability and Inhibition Profiles
Anne Makena et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates
Deanna J. Buehrle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2016)
What is the role of the new -lactam/-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
Ivan Gentile et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2016)
Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections
Jose A. Hidalgo et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
The Carbapenem Inactivation Method (CIM), a Simple and Low-Cost Alternative for the Carba NP Test to Assess Phenotypic Carbapenemase Activity in Gram-Negative Rods
Kim van der Zwaluw et al.
PLOS ONE (2015)
Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries
Mariana Castanheira et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
David E. Ehmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Multiplex PCR for detection of acquired carbapenemase genes
Laurent Poirel et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Pseudomonas aeruginosa: resistance to the max
Keith Poole
FRONTIERS IN MICROBIOLOGY (2011)
Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study
Karthikeyan K. Kumarasamy et al.
LANCET INFECTIOUS DISEASES (2010)
Pseudomonas aeruginosa:: resistance and therapeutic options at the turn of the new millennium
N. Mesaros et al.
CLINICAL MICROBIOLOGY AND INFECTION (2007)
Share Paper
